Coherus, Amgen Settle Patent Suit on Arthritis Biosimilar Drug

Coherus and Amgen dropped a lawsuit in which Coherus claimed Amgen’s biosimilar of AbbVie’s blockbuster arthritis drug Humira infringes four patents for its own biosimilar version.

• No further details were provided in a notice of agreement, approved Tuesday in federal court in Wilmington, Delaware
• Amgen launched Amgevita, a biosimilar of Humira, in Europe in October 2018
  • Amgevita is sold only in Europe but is made in the U.S., which Coherus alleged as infringement of its patents
• Biosimilars are nearly identical versions of branded biological drugs and are made from living organisms
• Amgen’s U.S. version, called Amgevita, won’t come to market ...